Micro-Cap BIOREGENX Narrows Q1 Net Loss by 90% Amid Restructuring Efforts
BRGX sits 22% above its 52-week low of $0.007.
Summary
BIOREGENX, INC. reported first-quarter 2026 results showing a significant 90.1% reduction in net loss, narrowing to ($26.42K) from ($266.85K) in the prior year. This substantial improvement in profitability comes despite a 17.3% decline in revenue to $426.18K, attributed to product quality issues with its medical testing machine. The company actively reduced SG&A by 33% to conserve cash and acquired DocSun assets as part of a strategic restructuring. This financial update is critical, especially following the previous 10-K's disclosure of substantial doubt about the company's ability to continue as a going concern, as it indicates proactive management efforts to control expenses and address operational challenges. Investors will be watching for continued progress on revenue stabilization and further improvements in profitability as restructuring efforts proceed.
At the time of this announcement, BRGX was trading at $0.01 on OTC in the Life Sciences sector, with a market capitalization of approximately $8.7M. The 52-week trading range was $0.01 to $0.03. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.